The FDA picked the LP.8.1 Covid strain for the fall vaccines, fueling concerns that the shots may be limited to only the most ...

Low uptake may reflect barriers—misinformation, access or shifting insurance coverage—not simply waning need.

FDA's new COVID-19 vaccine policy may restrict low-risk individuals' access, pending clinical trials to prove benefits.

The FDA will encourage new clinical trials on the widely used vaccines before approving them for children and healthy adults.

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

Vaccine advisers to the FDA decided Thursday that only strains of the JN.1 variant should be targeted by updated versions of covid vaccines that will be available next fall and winter. Separately, ...

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

Despite an explanation of the new strategy published Tuesday from FDA Commissioner Marty Makary and Vinay Prasad, who ...

San Diego doctors are expressing apprehension about the new policy on COVID-19 vaccines rolled out by the U.S. Food and Drug ...

WASHINGTON (AP) — A government report released on Thursday covering wide swaths of American health and wellness reflects some ...

The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their ...

The vaccine eligibility change is a threat to the health of Americans, some experts say, adding that the FDA is not being ...